


Abbott Laboratories (Pakistan) Limited

City Office: 8th Floor Faysal House
 ST-02, Sharah-e-Faisal, Karachi-75350
 P.O. Box 7229 Karachi 74400
 Tel : (92-21) 111-Abbott (111-222-688)
 : (92-21) 32799018-19
 Fax : (92-21) 32800244

Abbott Laboratories (Pakistan) Limited

Registered Office: Opp. Radio Pakistan
 Transmission Centre, Hyderabad Road,
 Landhi, Karachi-75120
 P.O. Box 7229, Karachi 74400
 Tel : (92-21) 35069748-49
 Fax : (92-21) 35001903

August 28th, 2023

The General Manager
 Pakistan Stock Exchange Limited
 Stock Exchange Building
 Stock Exchange Road
 Karachi

Sub: Financial Results for the Half year ended June 30th 2023

Dear Sir,

We have to inform you that the Board of Directors of our company in their meeting held on Monday, August 28th, 2023 at 12:00 p.m at Abbott Laboratories (Pakistan) Limited, 8th Floor, Faysal House, Shahrah-e-Faisal, Karachi, considered and approved the financial results of the Company as follows:

	<u>Six Months Ended</u>		<u>Quarter Ended</u>	
	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
----- (Rupees in ' 000) -----				
NET SALES				
Local	25,820,340	23,716,332	12,771,326	12,193,220
Export	1,422,838	964,097	665,934	716,050
	<u>27,243,178</u>	<u>24,680,429</u>	<u>13,437,260</u>	<u>12,909,270</u>
Cost of sales	(21,438,142)	(16,219,085)	(10,839,534)	(8,529,082)
GROSS PROFIT	<u>5,805,036</u>	<u>8,461,344</u>	<u>2,597,726</u>	<u>4,380,188</u>
Selling and distribution expenses	(4,125,152)	(3,611,354)	(2,063,340)	(1,795,199)
Administrative expenses	(513,882)	(422,077)	(261,943)	(214,499)
Other charges	(1,572,885)	(793,659)	(98,948)	(539,703)
Other income	1,063,753	475,132	226,239	249,799
	<u>(5,148,166)</u>	<u>(4,351,958)</u>	<u>(2,197,992)</u>	<u>(2,299,602)</u>
	656,870	4,109,386	399,734	2,080,586
Finance costs	<u>(16,927)</u>	<u>(28,121)</u>	<u>(7,861)</u>	<u>(13,175)</u>
PROFIT BEFORE TAXATION	<u>639,943</u>	<u>4,081,265</u>	<u>391,873</u>	<u>2,067,411</u>
Taxation				
Current	(1,084,793)	(1,306,375)	(480,286)	(730,978)
Prior	(356,210)	(841,262)	(356,210)	(841,262)
Deferred	1,693	(153,615)	(135,223)	(156,937)
	<u>(1,439,310)</u>	<u>(2,301,252)</u>	<u>(971,719)</u>	<u>(1,729,177)</u>
NET (LOSS) / PROFIT FOR THE PERIOD	<u>(799,367)</u>	<u>1,780,013</u>	<u>(579,846)</u>	<u>338,234</u>
BASIC AND DILUTED (LOSS) / EARNINGS PER SHARE (Rs. Per share)	<u>(8.17)</u>	<u>18.18</u>	<u>(5.93)</u>	<u>3.45</u>



The Quarterly Report of the Company for the period ended June 30, 2023 will be transmitted through PUCARS separately, within the specified time.

Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED


SYED ANIS AHMED
CHIEF EXECUTIVE &
MANAGING DIRECTOR